Citations

Clear

6421 citation(s) found for "Su, Christopher".

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials
Armstrong, Andrew J. , Liu, Vinnie Y.T. , Selvaraju, Ramprasaath R., Chen, Emmalyn , Simko, Jeffry, DeVries, Sandy, Sartor, Oliver , Sandler, Howard M. , Mohamad, Osama , Huang, Huei–Chung, Griffin, Jacqueline , Esteva, Andre , Carson, John H., Peters, Christopher A., Gore, Elizabeth , Monson, Jedidiah M., Augspurger, Mark E., El‐Gayed, Ali , Rodgers, Joseph P., McKay, Rana R. , Morgan, Todd M. , Feng, Felix Y. , Nguyen, Paul L. , Tran, Phuoc T , Spratt, Daniel E , Lee, Steve P , El-Gayed, Ali , McKay, Rana R , Morgan, Todd M , Feng, Felix Y , Sartor, A Oliver , Sandler, Howard M , Armstrong, Andrew J , Yamashita, Rikiya , Spratt, Daniel E. , Carson, John Hi

Mayo Clinic

Journal of Clinical Oncology | April 16, 2025 | Volume: 43 | Issue: 32 | Pages: 3494-3504

10.1200/jco.24.00365 | PMID 40239134 Get It

PURPOSE Long-term androgen deprivation therapy (ADT) improves survival in men with high-risk localized prostate cancer (PCa) receiving radiotherapy (RT). Predictive biomarkers are needed to guide ADT duration. METHODS A multimodal artificial intelligence (MMAI)–derived predictive biomarker was trained for long-term (LT) versus short-term (ST) ADT using pretreatment digital prostate biopsy images and clinical data (age, prostate-specific antigen, Gleason, and T stage) from six NRG Oncology phase III randomized radiotherapy trials. The novel MMAI-derived biomarker was developed to predict the differential benefit of LT-ADT on the primary end point, distant metastasis (DM). MMAI predictive utility was validated on a seventh randomized trial, RTOG 9202 (N = 1,192), which randomly assigned men to RT + ST-ADT (4 months) versus RT + LT-ADT (28 months). Fine-Gray and cumulative incidence analyses for DM, and secondarily, death with DM, were performed. Deaths without DM were treated as competing risks. RESULTS In the validation cohort (median follow-up, 17.2 years), LT-ADT significantly improved DM from 26% to 17% (subdistribution hazard ratio [sHR], 0.64 [95% CI, 0.50 to 0.82], P < .001). A significant biomarker-treatment predictive interaction was observed ( P = .04) for DM, whereby MMAI biomarker–positive men (n = 785, 66%) had reduced DM with LT-ADT versus ST-ADT (sHR, 0.55 [95% CI, 0.41 to 0.73], P < .001), whereas no treatment benefit was observed for MMAI biomarker–negative men (n = 407; sHR, 1.06 [95% CI, 0.61 to 1.84], P = .84). The estimated 15-year DM risk difference between RT + LT-ADT and RT + ST-ADT was 14% in MMAI biomarker–positive men and 0% in MMAI biomarker–negative men. The MMAI biomarker was also prognostic for DM, irrespective of treatment (sHR, 2.35 [95% CI, 1.72 to 3.19], P < .001). CONCLUSION To our knowledge, the MMAI model is the first validated predictive biomarker to guide ADT duration with RT in localized/locally advanced PCa. Approximately one third of men with high-risk PCa could safely be spared the additional 24 months of ADT and the associated morbidity.
The Use of an Artificial Intelligence Platform OpenEvidence to Augment Clinical Decision-Making for Primary Care Physicians
Stephenson, Christopher R. , Gilman, Elizabeth A. , Aakre, Christopher A. , Croghan, Ivana T. , Mundi, Manpreet S. , Ghosh, Karthik, Varayil, Jithinraj Edakkanambeth , Hurt, Ryan T. , Gilman, Elizabeth A , Croghan, Ivana T , Mundi, Manpreet S , Edakkanambeth Varayil, Jithinraj, Ghosh, Karthik , Edakkanambeth Varayil, Jithinraj

Mayo Clinic

Journal of Primary Care & Community Health | April 16, 2025 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/21501319251332215 | PMID 40238861 Get It

Background: Artificial intelligence (AI) platforms can potentially enhance clinical decision-making (CDM) in primary care settings. OpenEvidence (OE), an AI tool, draws from trusted sources to generate evidence-based medicine (EBM) recommendations to address clinical questions. However, its effectiveness in real-world primary care cases remains unknown. Objective: To evaluate the performance of OE in providing EBM recommendations for five common chronic conditions in primary care: hypertension, hyperlipidemia, diabetes mellitus type 2, depression, and obesity. Methods: Five patient cases were retrospectively analyzed. Physicians posed specific clinical questions, and OE responses were evaluated on clarity, relevance, evidence support, impact on CDM, and overall satisfaction. Four independent physicians provided ratings using a 0 to 4 scale. Results: OE provided accurate, evidence-based recommendations in all cases, aligning with physician plans. OE was scored on a scale of zero to four, where zero was very unclear, and four was very clear. Mean scores across cases were clarity (3.55 ± 0.60), relevance (3.75 ± 0.44), support (3.35 ± 0.49), and satisfaction (3.60 ± 0.60). However, the impact on CDM was limited (1.95 ± 1.05), as OE primarily reinforced rather than modified plans. Conclusion: OE was rated high in clarity, relevance, and evidence-based support, reinforcing physician decisions in common chronic conditions. While the impact on CDM was minimal due to the study’s retrospective nature, OE shows promise in augmenting the primary care physician. Prospective trials are needed to evaluate its utility in complex cases and multidisciplinary settings.
Microglia positron emission tomography and progression in multiple sclerosis: thalamus on fire
Zeydan, Burcu , Neyal, Nur , Son, Jiye , Schwarz, Christopher G. , Thomas, June C Kendall, Bush, Melissa L, Przybelski, Scott A. , Fought, Angela J. , Jack, Clifford R. , Petersen, Ronald C. , Kantarci, Kejal , Lowe, Val J. , Kantarci, Orhun H. , Kendall Thomas, June C, Morrison, Holly A, Jack, Clifford R , Kantarci, Kejal , Schwarz, Christopher G , Zeydan, Burcu , Thomas, June C Kendall, Morrison, Holly A, Bush, Melissa L, Reid, Robert I. , Airas, Laura M.

Mayo Clinic

Brain Communications | April 16, 2025 | Volume: 7 | Issue: 3 | Pages: No page available

10.1093/braincomms/fcaf141 | PMID 40322777 Get It

Abstract Increased innate immune activity promotes neurodegeneration and contributes to progression in multiple sclerosis. This prospective case-control study aims to investigate thalamic microglia density on 18kDa translocator protein PET in patients with multiple sclerosis using a third-generation radioligand, 11C-ER176, and investigate the associations of 11C-ER176 PET uptake with imaging and clinical measures of progression in multiple sclerosis. Patients with multiple sclerosis (n = 50) and controls (n = 55) were prospectively enrolled and they underwent 11C-ER176 PET and MRI including diffusion MRI with neurite orientation dispersion and density imaging. Disease characteristics, expanded disability status scale and multiple sclerosis functional composite scores were obtained in patients with multiple sclerosis. Age at imaging (mean ± standard deviation: patients = 49.6 ± 12.9 years, controls = 48.2 ± 15.4 years, P = 0.63) and sex (female ratio; patients = 72%, controls = 65%, P = 0.47) were not different between the groups. Thalamus 11C-ER176 PET uptake was highest in patients with progressive multiple sclerosis (1.272 ± 0.072 standardized uptake value ratio), followed by patients with relapsing multiple sclerosis (1.209 ± 0.074 standardized uptake value ratio) and lowest in controls (1.162 ± 0.067 standardized uptake value ratio, P &lt; 0.001). Patients with thalamic lesions had higher thalamus 11C-ER176 PET uptake than those without thalamic lesions in both relapsing multiple sclerosis and progressive multiple sclerosis (P &lt; 0.001). In patients with multiple sclerosis, higher thalamus 11C-ER176 PET uptake correlated with lower thalamic volume (r = −0.45, P = 0.001), higher mean diffusivity (r = 0.56, P &lt; 0.001), lower neurite density index (r = −0.43, P = 0.002), lower orientation dispersion index (r = −0.40, P = 0.005) and higher free water fraction (r = 0.42, P = 0.003) in the thalamus. In patients with multiple sclerosis, higher thalamus 11C-ER176 PET uptake also correlated with higher mean diffusivity (r = 0.47, P &lt; 0.001) and lower neurite density index (r = −0.36, P = 0.012) in the corpus callosum. In patients with multiple sclerosis, higher thalamus 11C-ER176 PET uptake correlated with worse expanded disability status scale scores (r = 0.33, P = 0.02), paced auditory serial addition test scores (r = −0.43, P = 0.003) and multiple sclerosis functional composite z-scores (r = −0.46, P = 0.001). Microglia density in the thalamus is highest in patients with progressive multiple sclerosis and is associated with imaging biomarkers of neurodegeneration and clinical disease severity. As a signature imaging biomarker of progression in multiple sclerosis, effectively reflecting the global disease burden, 11C-ER176 PET may aid development and efficacy evaluation of therapeutics targeting microglia.
Extreme Risk Protection Orders—Ethics for Clinicians
Ashok, Vivek A., Knoepke, Christopher E. , Burnett, Joel R. , Pasha, Amirala S , Ashok, Vivek , Pasha, Amirala S.

Mayo Clinic

JAMA Internal Medicine | April 14, 2025 | Volume: 185 | Issue: 6 | Pages: 617

10.1001/jamainternmed.2025.0519 | PMID 40227703 Get It

This Viewpoint discusses clinicians as legal petitioners of extreme risk protection orders to promote the safety and well-being of patients and communities.
Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes
Arenillas, Carlota , Celada, Lucía , Ruiz-Cantador, José , Calsina, Bruna , Datta, Debayan , García‐Galea, Eduardo , Fasani, Roberta , Moreno-Cárdenas, Ana Belén , Alba‐Linares, Juan José , Miranda, Berta , Martínez‐Montes, Ángel M. , Álvarez-Escolá, Cristina , Lecumberri, Beatriz , García, Ana González , Flores, Shahida K., Esquivel, Emmanuel , Ding, Yanli , Peitzsch, Mirko , Robles-Guirado, José-Ángel , Zapata, Rita Maria Regojo , Iglesias, Carmela , Dwight, Trisha , Oleaga, Amelia , Garrido‐Lestache, Elvira , Marín, María Jesús del Cerro , Martínez-Bendayán, Isaac , Álvarez-González, Enol , Cubiella, Tamara, Lourenço, Delmar Muniz , Pereira, Maria Adelaide Albergaria, Burnichon, Nelly , Broberg, Craig S. , Dickson, Paxton V. , Soriano, Joaquín Rueda , Dienstmann, Rodrigo , Villanueva, Josep , Capdevila, Jaume , Gimenez‐Roqueplo, Anne‐Paule , Bechmann, Nicole , Vaidya, Anand , Weghorn, Donate , Casteràs, Anna , Adameyko, Igor , Miranda-Barrio, Berta , González García, Ana , K Flores, Shahida , Regojo Zapata, Rita Maria , Pozo-Kreilinger, José Juan , Iglesias, Carmela , Dwight, Trisha , Muir, Christopher A , Oleaga, Amelia , Garrido-Lestache Rodríguez-Monte, Maria Elvira , Del Cerro, Maria Jesús , Martínez-Bendayán, Isaac , Álvarez-González, Enol , Cubiella, Tamara , Lourenço, Delmar Muniz , A Pereira, Maria Adelaide , Burnichon, Nelly , Buffet, Alexandre , Broberg, Craig , Dickson, Paxton V , Fraga, Mario F , Llorente Pendás, José Luis , Rueda Soriano, Joaquín , Buendía Fuentes, Francisco , Toledo, Sergio P A , Clifton-Bligh, Roderick , Dienstmann, Rodrigo , Villanueva, Josep , Capdevila, Jaume , Gimenez-Roqueplo, Anne-Paule , Favier, Judith , Nuciforo, Paolo , Young, W F , Bechmann, Nicole , Opotowsky, Alexander R , Vaidya, Anand , Bancos, Irina , Weghorn, Donate , Robledo, Mercedes , Casteràs, Anna , Dos-Subirà, Laura , Adameyko, Igor , Chiara, María-Dolores , Dahia, Patricia L M , Toledo, Rodrigo A , Fraga, Mario F. , Nucíforo, Paolo , Young, William F. , Bancos, Irina , Chiara, María‐Dolores , Dahia, Patricia L. M.

Mayo Clinic

Cancer Discovery | April 8, 2025 | Volume: 15 | Issue: 5 | Pages: 1037-1062

10.1158/2159-8290.cd-24-0943 | PMID 40199338 Get It

Abstract This study explores parallels between systemic hypoxia adaptation in high-altitude populations and tumorigenesis. We identified EPAS1, a gene critical for hypoxia adaptation in populations such as Tibetans and Sherpas, as playing a similar adaptive role in tumors arising under hypoxic conditions. Tumors from patients with chronic hypoxia displayed impaired DNA repair and frequent emergence of EPAS1 variants, with frequencies reaching up to 90%, echoing the positive selection seen in high-altitude dwellers. Mechanistically, EPAS1 gain-of-function mutations promote COX4I2 expression, reducing cellular oxygen consumption and supporting tumor proliferation in hypoxia. Analysis of clinical data from patients with hypoxia revealed tissue-specific and time-sensitive tumorigenic effects, particularly impacting oxygen-sensitive cells in the postnatal period. Our findings suggest that EPAS1-driven adaptation mechanisms in high-altitude populations provide a model for understanding tumor evolution under hypoxic stress, highlighting how genetic adaptations to diverse stressors in natural populations may yield insights into tumorigenesis and cancer progression. Significance: This study reveals a broad convergence in genetic adaptation to hypoxia between natural populations and tumors, suggesting that insights from natural populations could enhance our understanding of cancer biology and identify novel therapeutic targets. See related commentary by Lee, p. 875
Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment
Dima, Danai , Afrough, Aimaz , Goel, Utkarsh , Grajales‐Cruz, Ariel , Khouri, Jack , Julian, Kelley , Banerjee, Rahul , Razzo, Beatrice M. , Ferreri, Christopher J. , Martinez, Mariola Alejandra Vazquez, Davis, James A. , Sannareddy, Aishwarya , Raza, Shahzad , Portuguese, Andrew J. , Gaballa, Mahmoud , Rana, Masooma , DeJarnette, Shaun, Gonzalez, Rebecca , Mikkilineni, Lekha , Hosoya, Hitomi , Ouchveridze, Evguenia, Shune, Leyla , Lin, Yi , Sborov, Douglas W. , Anderson, Larry D. , Cowan, Andrew J., Patel, Krina K. , Voorhees, Peter M. , Sidana, Surbhi , Hansen, Doris K., Susanibar-Adaniya, Sandra P. , Grajales-Cruz, Ariel F , Banerjee, Rahul , Vazquez-Martinez, Mariola A , Davis, James A , Portuguese, Andrew J , Rana, Masooma S , Lieberman-Cribbin, Alex , Chen, Anna , Herr, Megan M. , Anwer, Faiz , Sborov, Douglas W , Garfall, Alfred L , Lee, Hans C , Anderson, Larry D , Patel, Krina , Voorhees, Peter , Sidana, Surbhi , Dima, Danai , Raza, Shahzad , Hosoya, Hitomi , Julian, Kelley L , Susanibar-Adaniya, Sandra P , Pasvolsky, Oren , Vazquez‐Martinez, Mariola , Puglianini, Omar Castañeda , Ouchveridze, Evguenia, Kaur, Gurbakhash , Rossi, Adriana , Anwer, Faiz , Richard, Shambavi , Baz, Rachid , Garfall, Alfred L. , Lee, Hans C. , Hansen, Doris K. , Atrash, Shebli

Mayo Clinic

Blood Advances | April 8, 2025 | Volume: 9 | Issue: 14 | Pages: 3408-3417

10.1182/bloodadvances.2025016059 | PMID 40198766 Get It

Abstract Outcomes of bispecific antibodies in patients with renal impairment (RI) are not well characterized, given the exclusion of these patients from clinical trials. Herein, we evaluated patients with relapsed/refractory multiple myeloma and RI treated with standard-of-care teclistamab. RI was defined as creatinine clearance (CrCl) &lt;40 mL/min. CrCl &lt;30 mL/min or dialysis dependence was defined as severe RI. Of the 384 included patients, 81 (21%) had RI, including 45 (18%) with severe RI, and 18 (5%) on dialysis. Patients with RI were more likely to be older (median age, 71 vs 67 years; P = .002) and have a higher median number of previous lines of therapy (7 vs 6; P = .04). Rates and severity of cytokine release syndrome (51% vs 59%; grade ≥3: 1.2% vs 1%) and immune effector cell–associated neurotoxicity syndrome (16% vs 13%; grade ≥3: 2.5% vs 2.6%) were similar in patients with and without RI, respectively. Patients with RI had higher baseline and day 30 post-teclistamab grade ≥3 anemia and grade ≥3 thrombocytopenia. Renal function did not worsen after teclistamab initiation in most patients with RI outside of the context of disease progression. Overall response rate (52% vs 56%; P = .61) and survival outcomes (median progression-free survival, 4.6 vs 6.5 months; P = .62) were comparable in patients with and without RI, respectively, after a median follow-up of 9.9 months. No differences in overall survival or non-relapse mortality were noted. Our findings suggest that treatment with teclistamab is feasible in patients with RI, including those on dialysis, with a similar safety and efficacy profile to patients without RI.
ReNeu: A Pivotal Phase 2b Trial of Mirdametinib in Children and Adults With Neurofibromatosis Type 1 (NF1)-Associated Symptomatic Plexiform Neurofibroma (PN) (S29.003)
Shuhaiber, Hans, Viskochil, David , Bielamowicz, Kevin , Lokku, Armend, Smith, L. Mary, Weintraub, Lauren , McNall‐Knapp, Rene , Hajjar, Fouad, Babovic‐Vuksanovic, Dusica , Moertel, Christopher L. , Hirbe, Angela C. , Sidhu, Alpa , Weber, Michael , Foreman, Nicholas K. , Gershon, Timothy R.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000209005 Get It

Application of a Clinical-electrophysiologic Model for Distinguishing Chronic Inflammatory Demyelinating Neuropathy (CIDP) in an Australian Cohort (P10-11.033)
Swart, Grace , Garg, Nidhi , Yiannikas, Con , Vucic, Ostoja, Pollard, John D. , Spies, Judith , Park, Susanna, Skolka, Michael P , Carroll, Antonia , Kiernan, Matthew C. , Klein, Christopher J.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000212523 Get It

Metastatic Choriocarcinoma Presents Challenge in Addressing Intracranial Pressure (P9-7.010)
Gvazava, Keti, Satyadev, Nihal , Peel, Jeffrey B. , Bendfeldt, Gabriel A. , Mutaz, Ahmed Ombada, Cebak, Johnny, Narvaez, Danelia Martinez, Matos, Nikki , Madala, Ansley, Kramer, Christopher M. , Ng, Lauren , Cebak, John E., Madala, Ansley, Freeman, William D.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000212518 Get It